Abstract: Provided are: a novel anti-ROR1 antibody; a bispecific antibody comprising the anti-ROR1 antibody; and uses thereof.

Abstract: Provided are a pharmaceutical composition and a method for the treatment and/or prevention of HER2-low expressing and/or Fc?RI-expressing cancers using anti-4-1BB/anti-HER2 bispecific antibodies.

Abstract: Provided are an anti-4-1BB/anti-HER2 bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

Abstract: The present disclosure provides a polynucleotide encoding the anti-PD-L1/anti-4-1BB bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between 4-1BB and its ligand. The bispecific antibody may have high binding affinity to both of a PD-L1 protein and a 4-1BB protein.

Abstract: Provided are an antibody or antigen-binding fragment thereof that specifically binds to a B-cell maturation antigen (BCMA), a method of preparing the same, and use thereof. Accordingly, these can be utilized in effectively preventing or treating cancers.

Abstract: Provided are anti-CLL-1 antibodies and uses thereof, according to the anti-CLL-1 antibody of one aspect, it can bind to CLL-1 with high binding affinity, and can cause activation of T cells, thus it can be used effectively for preventing or treating the cancer expressing CLL-1.

Abstract: Provided are an anti-4-1BB/anti-HER2 bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

Abstract: Provided are an anti-4-1BB/anti-EGFR bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

Abstract: Provided is an anti-4-1BB antibody or an antigen-binding fragment thereof, and uses thereof.

Abstract: The present disclosure provides an anti-PD-L1/anti-4-1BB bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between 4-1BB and its ligand. The bispecific antibody may have high binding affinity to both of a PD-L1 protein and a 4-1BB protein.

Abstract: The present disclosure provides an anti-PD-L1/anti-LAG3 bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between LAG3 and its ligand (e.g., a MHC class II molecule and FGL1). The bispecific antibody may have high binding affinity to both of a PD-L1 protein (e.g., a human PD-L1 protein) and a LAG3 protein (e.g., a human LAG3 protein). Also provided are antibodies and fragments that have specificity to the PD-L1 or LAG3 protein alone, or antibodies and fragments having additional specificity to one or more other antigens.

Abstract: Provided are an anti-4-1BB/anti-EGFR bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

Abstract: The present disclosure provides an anti-B7-H4/anti-4-1BB bispecific antibody capable to effectively block the T-cell inhibitory effect of B7-H4 on the surface of tumor cells, and simultaneously activate 4-1BB on T-cells. The bispecific antibody may have high binding affinity to both of a B7-H4 protein (e.g., a human, monkey and mouse B7-H4 protein) and a 4-1BB protein (e.g., a human, monkey and mouse 4-1BB protein). The present disclosure also provides an anti-B7-H4 antibody specifically binds to B7-H4 protein.

Abstract: The present invention discloses an anti-ROR1 antibody specifically recognizing human and mouse ROR1. The monoclonal antibody can be usefully used for cancer targeting treatment including detection of various cancer expressing ROR1 through specific binding, and drug delivery to specific cancer, etc. as well as a cancer therapeutic agent, by inhibiting tumors.

Abstract: Provided is an anti-B7-H3 antibody specifically recognizing a B7-H3, which can be usefully as a cancer therapeutic agent, as having an inhibitory activity of an immune checkpoint which induces antibody-dependent cell-mediated cytotoxicity and T cell activation inhibited by B7-H3. In particular, the antibody having the inhibitory activity of an immune checkpoint can be used in combination with other immunoantibody therapeutic agents. In addition, it can be usefully used for cancer targeting treatment including detection of various cancers expressing B7-H3 through specific binding to B7-H3, and drug delivery to specific cancer, etc.

Abstract: The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.

Abstract: The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.

Abstract: The present disclosure provides an anti-PD-L1/anti-LAG3 bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between LAG3 and its ligand (e.g., a MHC class II molecule and FGL1). The bispecific antibody may have high binding affinity to both of a PD-L1 protein (e.g., a human PD-L1 protein) and a LAG3 protein (e.g., a human LAG3 protein). Also provided are antibodies and fragments that have specificity to the PD-L1 or LAG3 protein alone, or antibodies and fragments having additional specificity to one or more other antigens.

Abstract: Provided is an anti-4-1 BB antibody or an antigen-binding fragment thereof, and uses thereof.

Abstract: The present disclosure provides an anti-PD-L1/anti-4-1BB bispecific antibody capable to effectively block the interactions between PD-L1 and its receptor PD-1 and between 4-1BB and its ligand. The bispecific antibody may have high binding affinity to both of a PD-L1 protein and a 4-1BB protein.